Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is ambitious when measured by our usual standards. As the designated Pharmalot groundskeeper, we plan to beautify the grounds. We also hope to make time to promenade with the official mascot, indulge our shortest person, and catch up on our reading (a book about spies awaits). And what about you? This is a fine time to make a vaccine appointment. Those of you who see that your cup is half full could plan a getaway for later this year. Or you could simply enjoy the great outdoors. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

AstraZeneca (AZN) has struggled to pull together the full data necessary to apply for U.S. approval of its Covid-19 shot, further delaying its efforts to secure a go-ahead from the Food and Drug Administration, The Wall Street Journal reports. The company said last month that it would apply for emergency use authorization for its vaccine by mid-April. It has recently told U.S. officials it might need until mid-May to finish its application for an FDA review.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.